Disease Clusters | GeDiPNet

Cluster 22

24 diseases · 49 shared-gene connections

24 Diseases

334 Unique genes

0.115 Avg. similarity score

Hyperkinesia Most-connected disease (9 links)

Significant edges only (q < 0.05) Spacing Colour by

Disease Searched: Neurodevelopmental disorder with or without variable movement or behavioral abnormalities Pinned (dragged)

Node size = connections within this cluster · edge thickness = similarity strength · hover an edge for its details · click a node to select it and show its pairs below (double-click or Ctrl/⌘-click opens the disease page) · drag a node to pin it in place · scroll/pinch to zoom.

Neurodevelopmental disorder with or without variable movement or behavioral abnormalities Hyperkinesia Chiari-frommel syndrome Disruptive impulse-control and conduct disorder Dyskinesia, drug-induced Hypotension

Member diseases (most connected first ‐ the cluster's core)

Disease ⇵	Connections in cluster ⇵	Significant partners ⇵	Curated genes ⇵
Hyperkinesia	9	9	33
Chiari-frommel syndrome	7	7	7
Disruptive impulse-control and conduct disorder	7	7	5
Dyskinesia, drug-induced	7	7	15
Hypotension	7	7	67
Bradycardia	6	6	26
Hyperproinsulinemia	6	6	9
Myoclonic dystonia	6	6	5
Catalepsy	5	5	16
Pituitary neoplasms	5	5	7
Amphetamine or sympathomimetic abuse	4	4	77
Delirium	4	4	10
Dyskinesia	4	4	26
Amnesia	3	3	18
Hypogonadotropic hypogonadism 23 with or without anosmia	3	3	1
Anhedonia	2	2	26
Edema	2	2	49
Hyperalgesia	2	2	89
Intellectual developmental disorder, autosomal dominant 67	2	2	1
Neurodevelopmental disorder with language delay and variable cognitive abnormalities	2	2	1
Neurodevelopmental disorder with or without variable movement or behavioral abnormalities	2	2	1
Neurodevelopmental disorder with language impairment and behavioral abnormalities	1	1	1
Retrograde amnesia	1	1	1
Substance-induced psychosis	1	1	17

Top shared genes (genes linked to 2+ member diseases)

Gene ⇵	Member diseases ⇵	Linked diseases
DRD2	14 / 24	Amphetamine or sympathomimetic abuse, Anhedonia, Bradycardia, Catalepsy and 10 more
PDYN	7 / 24	Amnesia, Amphetamine or sympathomimetic abuse, Bradycardia, Dyskinesia and 3 more
PRL	7 / 24	Bradycardia, Catalepsy, Chiari-frommel syndrome, Disruptive impulse-control and conduct disorder and 3 more
DRD3	6 / 24	Amphetamine or sympathomimetic abuse, Delirium, Disruptive impulse-control and conduct disorder, Dyskinesia, drug-induced and 2 more
DRD1	5 / 24	Amphetamine or sympathomimetic abuse, Catalepsy, Dyskinesia, drug-induced, Hyperkinesia and 1 more
IL6	5 / 24	Amnesia, Delirium, Edema, Hyperalgesia and 1 more
POMC	5 / 24	Amnesia, Bradycardia, Catalepsy, Edema and 1 more
SLC6A3	5 / 24	Amphetamine or sympathomimetic abuse, Anhedonia, Delirium, Hyperkinesia and 1 more
TAC1	5 / 24	Amnesia, Bradycardia, Edema, Hyperalgesia and 1 more
ADORA2A	4 / 24	Amphetamine or sympathomimetic abuse, Hyperkinesia, Hypotension, Substance-induced psychosis
AGT	4 / 24	Bradycardia, Catalepsy, Hyperalgesia, Hypotension
CALCA	4 / 24	Catalepsy, Edema, Hyperalgesia, Hyperkinesia
COMT	4 / 24	Amphetamine or sympathomimetic abuse, Anhedonia, Dyskinesia, Hyperalgesia
GAD1	4 / 24	Amphetamine or sympathomimetic abuse, Chiari-frommel syndrome, Dyskinesia, drug-induced, Hyperproinsulinemia
GCG	4 / 24	Bradycardia, Catalepsy, Hyperkinesia, Hypotension
KCNN2	4 / 24	Dyskinesia, Edema, Myoclonic dystonia, Neurodevelopmental disorder with or without variable movement or behavioral abnormalities
KNG1	4 / 24	Bradycardia, Edema, Hyperalgesia, Hypotension
LHB	4 / 24	Bradycardia, Chiari-frommel syndrome, Hyperproinsulinemia, Hypogonadotropic hypogonadism 23 with or without anosmia
OPRM1	4 / 24	Amphetamine or sympathomimetic abuse, Dyskinesia, Hyperalgesia, Substance-induced psychosis
TH	4 / 24	Catalepsy, Delirium, Dyskinesia, drug-induced, Hyperkinesia
ADORA1	3 / 24	Bradycardia, Catalepsy, Hypotension
AVP	3 / 24	Amnesia, Hyperalgesia, Hypotension
CAT	3 / 24	Dyskinesia, drug-induced, Edema, Hypotension
CCK	3 / 24	Catalepsy, Dyskinesia, drug-induced, Hyperkinesia
CNR1	3 / 24	Catalepsy, Hyperalgesia, Hypotension
CRH	3 / 24	Anhedonia, Bradycardia, Hypotension
CRHR1	3 / 24	Anhedonia, Hyperalgesia, Hyperkinesia
CXCL8	3 / 24	Delirium, Edema, Hyperalgesia
EDN1	3 / 24	Bradycardia, Hyperalgesia, Hypotension
FOS	3 / 24	Amphetamine or sympathomimetic abuse, Hyperalgesia, Hyperkinesia
GABBR1	3 / 24	Amphetamine or sympathomimetic abuse, Hyperkinesia, Neurodevelopmental disorder with language delay and variable cognitive abnormalities
GDNF	3 / 24	Amphetamine or sympathomimetic abuse, Dyskinesia, drug-induced, Hyperalgesia
GNRH1	3 / 24	Bradycardia, Chiari-frommel syndrome, Hyperproinsulinemia
GRIA1	3 / 24	Hyperkinesia, Hypotension, Intellectual developmental disorder, autosomal dominant 67
HTR1A	3 / 24	Anhedonia, Bradycardia, Substance-induced psychosis
HTR2A	3 / 24	Dyskinesia, Hyperalgesia, Hyperkinesia
IGF1	3 / 24	Delirium, Hyperalgesia, Pituitary neoplasms
IL1A	3 / 24	Amnesia, Hyperalgesia, Hypotension
IL2	3 / 24	Amnesia, Hyperkinesia, Hypotension
INS	3 / 24	Edema, Hyperproinsulinemia, Hypotension
NGF	3 / 24	Amnesia, Hyperalgesia, Hyperkinesia
NTS	3 / 24	Bradycardia, Catalepsy, Hyperkinesia
OXT	3 / 24	Edema, Hyperkinesia, Hypotension
TNF	3 / 24	Edema, Hyperalgesia, Hypotension
TRH	3 / 24	Amnesia, Bradycardia, Catalepsy
VIP	3 / 24	Edema, Hyperalgesia, Hypotension
ACE	2 / 24	Hypotension, Substance-induced psychosis
AKT1	2 / 24	Amphetamine or sympathomimetic abuse, Substance-induced psychosis
APOE	2 / 24	Amnesia, Delirium
ATP1A3	2 / 24	Anhedonia, Dyskinesia
BDKRB2	2 / 24	Hyperalgesia, Hypotension
CACNA1D	2 / 24	Bradycardia, Edema
CNR2	2 / 24	Catalepsy, Hyperalgesia
CYP2D6	2 / 24	Amphetamine or sympathomimetic abuse, Bradycardia
DISC1	2 / 24	Anhedonia, Hyperkinesia
EDN2	2 / 24	Bradycardia, Hypotension
EDN3	2 / 24	Bradycardia, Hypotension
FOSB	2 / 24	Disruptive impulse-control and conduct disorder, Dyskinesia, drug-induced
GJA1	2 / 24	Anhedonia, Hyperalgesia
GRIA2	2 / 24	Hyperkinesia, Neurodevelopmental disorder with language impairment and behavioral abnormalities
GRIN2B	2 / 24	Hyperalgesia, Hypotension
GRM2	2 / 24	Amphetamine or sympathomimetic abuse, Substance-induced psychosis
GSTP1	2 / 24	Amphetamine or sympathomimetic abuse, Substance-induced psychosis
HTR1B	2 / 24	Amphetamine or sympathomimetic abuse, Hypotension
HTR6	2 / 24	Amphetamine or sympathomimetic abuse, Substance-induced psychosis
IL1B	2 / 24	Hyperalgesia, Hypotension
IL1RN	2 / 24	Delirium, Hyperalgesia
MAPK1	2 / 24	Anhedonia, Hyperalgesia
NISCH	2 / 24	Bradycardia, Hypotension
NOS1	2 / 24	Amphetamine or sympathomimetic abuse, Hyperalgesia
NPY1R	2 / 24	Amphetamine or sympathomimetic abuse, Substance-induced psychosis
PGR	2 / 24	Chiari-frommel syndrome, Hyperproinsulinemia
PICK1	2 / 24	Amphetamine or sympathomimetic abuse, Substance-induced psychosis
PLAT	2 / 24	Amphetamine or sympathomimetic abuse, Hypotension
PNOC	2 / 24	Hyperalgesia, Hypotension
PPP1R1B	2 / 24	Catalepsy, Dyskinesia
PREP	2 / 24	Amnesia, Retrograde amnesia
PRLR	2 / 24	Chiari-frommel syndrome, Hyperproinsulinemia
PTGS2	2 / 24	Edema, Hyperalgesia
PTHLH	2 / 24	Edema, Hyperalgesia
RGS9	2 / 24	Dyskinesia, drug-induced, Substance-induced psychosis
SLC6A4	2 / 24	Amphetamine or sympathomimetic abuse, Anhedonia
SLC9A3	2 / 24	Edema, Hypotension
SNCA	2 / 24	Amphetamine or sympathomimetic abuse, Substance-induced psychosis
TACR1	2 / 24	Bradycardia, Hyperalgesia

What do these columns mean?

Connections in cluster: How many other members this disease has a shared-gene link to (the node size in the network above). The most-connected diseases are the cluster's core.
Significant partners: How many of those links are statistically significant (FDR q < 0.05).
Curated genes: Distinct curated genes linked to that disease in GeDiPNet.
Member diseases (Top shared genes): How many of this cluster's diseases are linked to the gene, out of the cluster's total. Genes shared by many members are the most direct explanation of why they group together.
Overlap genes (x / y): x = genes shared between this cluster and the pathway/GO term; y = that pathway/GO term's total gene count. A higher x relative to y (and to the cluster's own size) means a tighter biological match.
Cluster gene count: Total distinct genes across every disease in this cluster -- the "n" used in the significance test below.
Fold enrichment: Observed overlap divided by the overlap expected by chance, given the cluster's gene count, the pathway/term's size and the gene universe tested. 5× means five times more shared genes than random. Tells strong hits apart when q-values are all vanishingly small.
P-value / FDR q-value: Is this pathway/GO term's overlap with the cluster more than chance? Upper-tail hypergeometric test, Benjamini-Hochberg corrected across every tested pathway/term (prefer the q-value -- it accounts for testing many at once).
Shared genes (Pairs within this cluster): Number of curated genes the two diseases in that row have in common.
Similarity score (Pairs within this cluster): Jaccard-based gene overlap between the two specific diseases in that row -- same metric as the main Shared-Gene Disease Pairs page.

Enriched Pathways (why this cluster is grouped, biologically)

Pathway ⇵	Source ⇵	Overlap genes ⇵	Fold enrichment ⇵	P-value ⇵	FDR q-value ⇵
Neuroactive ligand-receptor interaction AVP, GRP, HRH3, PDYN, POMC, TAC1, TRH, ADORA2A, DRD1, DRD2, DRD3, DRD4	KEGG	76 / 370	7.4×	2.31e-45	2.27e-41 ✓ sig.
cAMP signaling pathway GNAI1, GNAI3, POMC, ADORA2A, AKT1, BDNF, DRD1, DRD2, FOS, GABBR1, HTR1B, HTR6	KEGG	54 / 226	8.6×	1.21e-35	6.45e-32 ✓ sig.
Hormone signaling AVP, GNAI1, GNAI3, PDYN, POMC, TRH, DRD1, DRD2, DRD3, DRD4, NOS1, OPRM1	KEGG	52 / 219	8.5×	3.55e-34	1.51e-30 ✓ sig.
Peptide ligand-binding receptors GRP, PDYN, POMC, TRH, NPY1R, OPRM1, PROKR2, MC4R, OPRK1, AGT, EDN1, EDN2	Reactome	34 / 106	11.5×	2.50e-27	5.87e-24 ✓ sig.
Serotonergic synapse APP, GNAI1, GNAI3, CYP2D6, HTR1B, HTR3A, HTR6, SLC6A4, CACNA1C, HTR1A, MAPK1, CACNA1D	KEGG	28 / 115	8.8×	4.56e-19	2.96e-16 ✓ sig.
Dopaminergic synapse GNAI1, GNAI3, AKT1, ARRB2, COMT, DRD1, DRD2, DRD3, DRD4, FOS, SLC6A3, CACNA1C	KEGG	29 / 132	7.9×	2.20e-18	1.27e-15 ✓ sig.
G alpha (i) signalling events APP, GNAI1, GNAI3, HRH3, PDYN, POMC, DRD3, DRD4, GABBR1, GRM2, HTR1B, NPY1R	Reactome	38 / 249	5.5×	5.61e-18	3.04e-15 ✓ sig.
G alpha (q) signalling events APP, AVP, GRP, TAC1, TRH, PROKR2, RGS17, AGT, EDN1, EDN2, EDN3, GCG	Reactome	32 / 172	6.7×	6.84e-18	3.57e-15 ✓ sig.
Cocaine addiction GNAI1, GNAI3, PDYN, BDNF, DRD1, DRD2, GRM2, RELA, SLC6A3, GNAI2, PPP1R1B, TH	KEGG	19 / 49	13.9×	1.46e-17	7.32e-15 ✓ sig.
Chagas disease GNAI1, GNAI3, IL2, IL6, AKT1, FOS, RELA, MAPK1, GNAI2, KNG1, CXCL8, GNAO1	KEGG	25 / 103	8.7×	4.12e-17	1.87e-14 ✓ sig.
Circadian entrainment GNAI1, GNAI3, FOS, NOS1, PRKG1, CACNA1C, MAPK1, CACNA1D, GNAI2, GNAO1, CACNA1H, CAMK2A	KEGG	23 / 97	8.5×	1.35e-15	4.57e-13 ✓ sig.
Calcium signaling pathway NGF, ADORA2A, DRD1, GDNF, HTR6, NOS1, CACNA1C, CACNA1D, CHRM2, TACR1, OXTR, HTR2A	KEGG	35 / 254	5.0×	3.18e-15	1.01e-12 ✓ sig.
Inflammatory mediator regulation of TRP channels NGF, KNG1, IGF1, HTR2A, MAP2K6, ALOX12, BDKRB1, BDKRB2, CAMK2A, IL1B, MAPK8, MAPK9	KEGG	22 / 99	8.0×	2.44e-14	6.46e-12 ✓ sig.
AGE-RAGE signaling pathway in diabetic complications IL1A, IL6, AKT1, RELA, MAPK1, AGT, EDN1, CXCL8, CASP3, TNF, AGER, CCL2	KEGG	22 / 101	7.8×	3.80e-14	9.74e-12 ✓ sig.
Amphetamine addiction PDYN, DRD1, FOS, SLC6A3, CACNA1C, CACNA1D, PPP1R1B, TH, FOSB, CAMK2A, GRIN1, GRIN2B	KEGG	18 / 69	9.4×	2.99e-13	6.24e-11 ✓ sig.

Enriched GO Terms (Biological Process, a second line of biological evidence)

GO term ⇵	GO ID ⇵	Overlap genes ⇵	Fold enrichment ⇵	P-value ⇵	FDR q-value ⇵
chemical synaptic transmission APP, HRH3, PDYN, TAC1, DRD4, GABRG2, GAD1, GAD2, GRM2, HTR1B, HTR3A, HTR6	GO:0007268	44 / 236	10.4×	4.71e-32	3.20e-28 ✓ sig.
signal transduction AVP, CSF2, GNAI1, GNAI3, GRP, HRH3, NGF, POMC, TRH, ADORA2A, AKT1, ARRB2	GO:0007165	108 / 2,125	2.8×	5.00e-25	1.56e-21 ✓ sig.
G protein-coupled receptor signaling pathway APOE, APP, GNAI1, GNAI3, HRH3, IL2, ADORA2A, AKT1, DRD1, DRD2, DRD3, DRD4	GO:0007186	69 / 1,031	3.7×	6.24e-22	1.33e-18 ✓ sig.
response to xenobiotic stimulus AVP, ADORA2A, COMT, DRD1, DRD2, DRD3, FOS, RELA, SLC6A3, SLC6A4, SNCA, CRH	GO:0009410	35 / 248	7.9×	1.90e-21	3.82e-18 ✓ sig.
response to ethanol AVP, IL2, DRD2, DRD3, FOS, GABBR1, GSTP1, RELA, SLC6A3, CRH, OPRK1, GNRH1	GO:0045471	25 / 110	12.7×	7.58e-21	1.39e-17 ✓ sig.
sensory perception of pain NGF, TAC1, ARRB2, NPY1R, OPRM1, OPRK1, PENK, AQP1, CCL2, HOXD1, MAPK3, MC1R	GO:0019233	18 / 44	22.9×	1.48e-20	2.55e-17 ✓ sig.
positive regulation of cytosolic calcium ion concentration AVP, IL2, TAC1, CD55, PRKG1, CACNA1C, CCR6, CCR7, EDN1, KNG1, TACR1, CALCA	GO:0007204	26 / 137	10.6×	1.61e-19	2.39e-16 ✓ sig.
vasodilation APOE, ADORA2A, DRD1, NOS1, PRKG1, ADORA1, KNG1, CALCA, INS, TNF, BDKRB2, GPER1	GO:0042311	18 / 50	20.1×	2.36e-19	3.43e-16 ✓ sig.
response to lipopolysaccharide TAC1, FOS, NOS1, RELA, SNCA, CCR7, IDO1, MAPK1, CYP1A1, EDN1, GNRH1, CNR2	GO:0032496	27 / 161	9.4×	9.12e-19	1.21e-15 ✓ sig.
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger HRH3, DRD1, DRD4, HTR1B, HTR6, NPY1R, OPRM1, HTR1A, CHRM2, CNR1, CNR2, HTR2A	GO:0007187	18 / 54	18.6×	1.19e-18	1.55e-15 ✓ sig.
neuropeptide signaling pathway GNAI1, GRP, PDYN, POMC, TAC1, NPY1R, OPRM1, PROKR2, RELA, OPRK1, NTS, PENK	GO:0007218	23 / 111	11.6×	2.63e-18	3.26e-15 ✓ sig.
response to hypoxia COMT, DRD2, NOS1, PLAT, SLC6A4, ADORA1, CYP1A1, EDN1, TH, LIF, CAT, PENK	GO:0001666	27 / 176	8.6×	9.78e-18	1.14e-14 ✓ sig.
regulation of blood pressure POMC, TAC1, COMT, NPY1R, AGT, EDN1, TACR1, UTS2, CALCA, GCH1, PTGS2, PTGS1	GO:0008217	20 / 83	13.5×	1.85e-17	2.07e-14 ✓ sig.
response to cocaine DRD1, DRD2, DRD3, GRM2, SLC6A3, SNCA, CRH, OPRK1, PITX3, FYN, FOSB, HTR2A	GO:0042220	14 / 35	22.4×	4.28e-16	3.70e-13 ✓ sig.
behavioral response to cocaine DRD1, DRD2, DRD3, DRD4, SLC6A4, SNCA, OPRK1, PPP1R1B, FOSB, HOMER1, HTR2A	GO:0048148	11 / 17	36.2×	5.68e-16	4.85e-13 ✓ sig.

Pairs within this cluster, by significance

Disease A ⇵	Disease B ⇵	Similarity score ⇵	Shared genes ⇵	P-value ⇵	FDR q-value ⇵
Bradycardia	Hypotension	0.175	14	1.75e-27	3.22e-26 ✓ sig.
Chiari-frommel syndrome	Hyperproinsulinemia	0.700	7	8.50e-25	1.45e-23 ✓ sig.
Hyperalgesia	Hypotension	0.106	15	1.94e-20	2.89e-19 ✓ sig.
Amphetamine or sympathomimetic abuse	Substance-induced psychosis	0.118	10	9.51e-20	1.38e-18 ✓ sig.
Bradycardia	Catalepsy	0.229	8	2.43e-19	3.48e-18 ✓ sig.
Catalepsy	Hypotension	0.105	8	9.97e-16	1.24e-14 ✓ sig.
Catalepsy	Hyperkinesia	0.163	7	1.14e-15	1.42e-14 ✓ sig.
Edema	Hypotension	0.093	10	8.19e-15	9.80e-14 ✓ sig.
Amnesia	Hypotension	0.089	7	6.29e-13	6.85e-12 ✓ sig.
Edema	Hyperalgesia	0.069	9	7.69e-12	7.78e-11 ✓ sig.
Amphetamine or sympathomimetic abuse	Dyskinesia, drug-induced	0.069	6	5.98e-11	5.70e-10 ✓ sig.
Hyperkinesia	Hypotension	0.074	7	8.03e-11	7.58e-10 ✓ sig.
Dyskinesia, drug-induced	Hyperkinesia	0.114	5	9.46e-11	8.84e-10 ✓ sig.
Bradycardia	Chiari-frommel syndrome	0.133	4	2.18e-10	1.98e-9 ✓ sig.
Amphetamine or sympathomimetic abuse	Hyperkinesia	0.067	7	2.19e-10	1.99e-9 ✓ sig.
Bradycardia	Hyperproinsulinemia	0.125	4	7.82e-10	6.81e-9 ✓ sig.
Catalepsy	Dyskinesia, drug-induced	0.143	4	1.03e-9	8.89e-9 ✓ sig.
Delirium	Hyperkinesia	0.100	4	3.55e-9	2.94e-8 ✓ sig.
Disruptive impulse-control and conduct disorder	Dyskinesia, drug-induced	0.167	3	7.34e-9	5.95e-8 ✓ sig.
Amnesia	Bradycardia	0.098	4	1.88e-8	1.45e-7 ✓ sig.
Delirium	Dyskinesia, drug-induced	0.130	3	8.78e-8	6.16e-7 ✓ sig.
Anhedonia	Hyperkinesia	0.071	4	2.47e-7	1.64e-6 ✓ sig.
Disruptive impulse-control and conduct disorder	Pituitary neoplasms	0.200	2	1.25e-6	7.51e-6 ✓ sig.
Chiari-frommel syndrome	Disruptive impulse-control and conduct disorder	0.182	2	1.75e-6	1.03e-5 ✓ sig.
Chiari-frommel syndrome	Pituitary neoplasms	0.167	2	2.62e-6	1.51e-5 ✓ sig.
Disruptive impulse-control and conduct disorder	Hyperproinsulinemia	0.154	2	3.00e-6	1.72e-5 ✓ sig.
Delirium	Disruptive impulse-control and conduct disorder	0.143	2	3.75e-6	2.12e-5 ✓ sig.
Hyperproinsulinemia	Pituitary neoplasms	0.143	2	4.50e-6	2.52e-5 ✓ sig.
Delirium	Pituitary neoplasms	0.133	2	5.62e-6	3.11e-5 ✓ sig.
Catalepsy	Disruptive impulse-control and conduct disorder	0.100	2	9.99e-6	5.40e-5 ✓ sig.
Anhedonia	Dyskinesia	0.060	3	1.06e-5	5.75e-5 ✓ sig.
Chiari-frommel syndrome	Dyskinesia, drug-induced	0.095	2	1.83e-5	9.64e-5 ✓ sig.
Dyskinesia	Myoclonic dystonia	0.067	2	2.70e-5	1.40e-4 ✓ sig.
Dyskinesia	Dyskinesia, drug-induced	0.050	2	2.81e-4	5.85e-4 ✓ sig.
Myoclonic dystonia	Neurodevelopmental disorder with or without variable movement or behavioral abnormalities	0.167	1	3.23e-4	6.41e-4 ✓ sig.
Chiari-frommel syndrome	Hypogonadotropic hypogonadism 23 with or without anosmia	0.125	1	4.52e-4	8.26e-4 ✓ sig.
Hyperproinsulinemia	Hypogonadotropic hypogonadism 23 with or without anosmia	0.100	1	5.81e-4	1.00e-3 ✓ sig.
Amnesia	Retrograde amnesia	0.053	1	1.16e-3	1.73e-3 ✓ sig.
Disruptive impulse-control and conduct disorder	Myoclonic dystonia	0.100	1	1.61e-3	2.26e-3 ✓ sig.
Bradycardia	Hypogonadotropic hypogonadism 23 with or without anosmia	0.037	1	1.68e-3	2.34e-3 ✓ sig.
Dyskinesia	Neurodevelopmental disorder with or without variable movement or behavioral abnormalities	0.037	1	1.68e-3	2.34e-3 ✓ sig.
Myoclonic dystonia	Pituitary neoplasms	0.091	1	1.94e-3	2.65e-3 ✓ sig.
Hyperkinesia	Intellectual developmental disorder, autosomal dominant 67	0.029	1	2.13e-3	2.85e-3 ✓ sig.
Hyperkinesia	Neurodevelopmental disorder with language delay and variable cognitive abnormalities	0.029	1	2.13e-3	2.85e-3 ✓ sig.
Hyperkinesia	Neurodevelopmental disorder with language impairment and behavioral abnormalities	0.029	1	2.13e-3	2.85e-3 ✓ sig.
Chiari-frommel syndrome	Myoclonic dystonia	0.083	1	2.26e-3	2.99e-3 ✓ sig.
Hyperproinsulinemia	Myoclonic dystonia	0.071	1	2.90e-3	3.71e-3 ✓ sig.
Hypotension	Intellectual developmental disorder, autosomal dominant 67	0.015	1	4.33e-3	5.28e-3 ✓ sig.
Amphetamine or sympathomimetic abuse	Neurodevelopmental disorder with language delay and variable cognitive abnormalities	0.013	1	4.97e-3	5.96e-3 ✓ sig.

Disease Clusters?